# A General Electric (GE) Healthcare FX2 Mel/M Automated Reaction Module for Probe Production

> **NIH NIH S10** · WASHINGTON UNIVERSITY · 2022 · $600,000

## Abstract

This application request funds for the purchase of a state-of-the-art automated radiosynthesis module and the
required hotcells needed to safely use and house the module components. This unit will be housed in the
Washington University School of Medicine (WUSM) Mallinckrodt Institute of Radiology (MIR) Cyclotron Facility
and Nuclear Pharmacy as a Shared Resource of our NIH sponsored researchers. The proposed instrument is the
General Electric (GE) Healthcare TRACERlab FX2 MeI/M automated reaction module with accompanying
Comecer hotcells. The addition of this equipment will allow a rapid escalation of research, development, and
routine production of materials needed by a variety of NIH supported projects. The intent of this equipment is to
allow both pre-clinical and clinical projects to have a flexible and routinely available piece of equipment to help
further their research objectives. This specific model of automated reaction module was selected due to its unique
capability to perform multiple Carbon-11 productions over the course of a single day without the need for users to
expose themselves to any residual radioactivity. The units are also identical to existing production units housed
within the Cyclotron Facility’s GMP production area, which are not available to researchers as shared
instruments. The ability for researchers to utilize identical instruments as those used for routine clinical
production, allows for a streamline bench-to-bedside process to be built in from the start of a
radiopharmaceuticals developmental path. This will aid in shortening the time required for translational work to
optimize a radiopharmaceutical’s production process, since the process will be directly transferrable to the GMP
production area. Shortening this time will mean more Investigational New Drug Applications (INDs) can be
developed and submitted to the FDA, which, in turn, will result in an increase in the numbers of clinical trials our
investigators can undertake. In this application, numerous NIH-supported projects are highlighted that will directly
benefit in multiple ways from the acquisition of this resource. This application includes a description of each NIH-
funded project that would directly benefit from this resource, a description of the scientific and technical expertise
of those individuals who will oversee and manage the resource, a plan for administration, and a strong
commitment from Washington University to provide support for the resource.

## Key facts

- **NIH application ID:** 10414705
- **Project number:** 1S10OD032172-01
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Michael L. Nickels
- **Activity code:** S10 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $600,000
- **Award type:** 1
- **Project period:** 2022-09-01 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10414705

## Citation

> US National Institutes of Health, RePORTER application 10414705, A General Electric (GE) Healthcare FX2 Mel/M Automated Reaction Module for Probe Production (1S10OD032172-01). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10414705. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*